Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in eosinophilic COPD with frequent exacerbations
NL-OMON59555Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of benralizumab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Primary endpoint: Annualized rate of moderate or severe COPD exacerbations. Started Aug 2020; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON59555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59555.